How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
View More
Towards Personalized Treatment Approaches in Soft Tissue Sarcomas
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Belantamab Mafodotin Combo Yields Improved OS in Relapsed/Refractory Multiple Myeloma
Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.
Imlunestrant +/- Abemaciclib Improves PFS in ER+/HER2– Advanced Breast Cancer Subgroup
Imlunestrant, alone or in combination, may provide an all-oral, targeted therapy option following progression for patients with ESR1-mutant, ER-positive, HER2-negative advanced breast cancer.
T-DXd Improves PFS in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer
December 11th 2024T-DXd improved PFS, vs treatment of physician’s choice, irrespective of time to progression or type of endocrine resistance among patients with hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR
Patients with mantle cell lymphoma in first complete response with undetectable MRD did not benefit from consolidative autologous transplant, according to results from the ECOG-ACRIN EA4151/BMT-CTN 1601 trial.
Adding Daratumumab to VRd Improves MRD Response in Newly Diagnose Myeloma
December 8th 2024An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as progression-free survival among patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.
NCCN Updates Guidelines for Preferred Frontline Regimen for Advanced Nasopharyngeal Carcinoma
The NCCN Guidelines Version 1.2025 for Cancer of the Nasopharynx listed toripalimab plus chemotherapy as the standalone preferred regimen in the frontline treatment of patients with advanced nasopharyngeal carcinoma.
Addition of Concomitant TTFields Induces OS Benefit in Unresectable Pancreatic Cancer
December 4th 2024The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its primary end point of overall survival in unresectable, locally advanced pancreatic adenocarcinoma.